Chemokines and Their Receptors

Roles in Specific Clinical Conditions and Measurement in the Clinical Laboratory

Massimo Locati, MD,1 Raffaella Bonecchi, PhD,1 and Massimiliano M. Corsi, MD, PhD,2

Key Words: Chemokines; Inflammation; Chemokine receptors; Cytokines, Biomarkers

In recent years, a number of cytokines have been recognized as important intercellular signals with a relevant role in the pathogenesis of several human diseases, which is mirrored by their growing relevance in clinical pathology as biomarkers of disease onset, progression, and remission.1 Leukocyte recruitment and activation are key steps in the pathogenesis of several human diseases. This process is coordinated by chemokines, a large subfamily of cytokines with chemotactic activity for different leukocyte subsets and an emerging role in major human diseases. After an overview of the chemokine system, this review briefly summarizes information available on clinical situations in which chemokine determination might be of diagnostic value with the aim to evaluate chemokines as new biomarkers of interest in clinical pathology.

The Chemokine System

The completion of the human genome project has led to the final identification in humans of about 50 structurally and functionally related molecules now recognized as a family of small secreted proteins and named chemokine because of their leukocyte chemotactic and cytokine-like activities. Chemokines bear a significant sequence identity to each other, and their protein structure is strictly dependent on 2 conserved disulfide bonds connecting conserved cysteine residues.2-4

According to cysteine number and spacing, 4 chemokine subfamilies have been defined [Figure 1]. The largest group of chemokines has the first 2 cysteines in an adjacent position (CC chemokines). Most of these molecules, products of a large multigenic cluster on chromosome 17q11.2, act on monocytes, whereas other CC chemokines, products of different chromosomal loci, are active on different cell types (Figure 1).
The other large group of chemokines has the first 2 of 4 total cysteines separated by an intervening amino acid (CXC chemokines). Most of these molecules are coded by 2 large multigenic clusters. The first, located on chromosome 4q12-q13, includes CXC chemokines containing an ELR-conserved amino acid sequence on the N-terminus (ELR+ CXC chemokines) that act on neutrophils. The second, located on 4q21.21, includes CXC chemokines lacking the ELR sequence (ELR− CXC chemokines) that act mainly on T lymphocytes (Figure 1).

| Family | Chromosome | Ligand | Receptor | Leukocyte |
|--------|------------|--------|----------|-----------|
| CXC    | 4q13-q21   | IL-8   | CXCR1    | PMN       |
|        | 4q21       | GCP-2  | CXCR1    | PMN       |
|        | 4q12-q13   | NAP-2  | CXCR2    | PMN       |
|        | 4q21       | ENA-78 | CXCR2    | PMN       |
|        |            | GROα   | CXCL1    |           |
|        |            | GROγ   | CXCL2    |           |
|        |            | IP-10  | CXCL3    |           |
|        |            | Mig    | CXCL9    | Th1, NK   |
|        | 4q21.2     | I-TAC  | CXCL11   |           |
|        | 10q11.1    | SDF-1α | CXCL12   |           |
|        | 4q21       | BCA-1  | CXCL13   |           |
|        | 17q13      | CXCL16 | CXCR6    | T act     |
|        | 5q31       | BRAK   | CXCL14   | Mo        |
|        | 17q11.2    | MCP-1  | CCL2     | Mo, NK, Ba, iDC, T act, B |
|        | 17q12      | MCP-2  | CCL8     | Mo, NK, Ba, iDC, T act, B |
|        | 17q11.2    | MIP-1α | CCL3     | Mo, Mo, Th1, T act, NK |
|        | 17q11.2    | RANTES | CCL5     | Mo, Mo, iDC, NK |
|        | 17q12      | MPIF-1 | CCL23    | Mo, Mo, iDC, NK |
|        | 17q11.2    | HCC-1  | CCL14    | Mo, Mo, iDC, NK |
|        | 17q11.2    | HCC-2  | CCL15    | Mo, Mo, iDC, NK |
|        | 17q11.2    | HCC-4  | CCL16    | Mo, Mo, iDC, NK |
|        | 17q21.1    | Eotaxin | CCL11   | Mo, Mo, iDC, NK |
|        | 7q11.23    | Eotaxin | CCL21   | Mo, Mo, iDC, NK |
|        | 16q13      | TARC   | CCL17    | iDC, Th2, NK, T skin, Mo |
|        | 2q33-q37   | MP-3α  | CCL20    | iDC, Th2, NK, T skin, Mo |
|        | 9p13       | ELC    | CCL19    | iDC, Th2, NK, T skin, Mo |
|        | 9p13       | SLC    | CCL21    | iDC, Th2, NK, T skin, Mo |
|        | 17q12      | I-309  | CCL1     | Mo, iDC, Th2, T reg |
|        | 19p13.2    | TECK   | CCL25    | T, T muc |
|        | 9p13       | CTACK  | CCL27    | T, T muc |
|        | 17q11.2    | PARC   | CCL18    | T, T muc, T skin |
|        | 1q23       | Lymphotactin | XCL1 | Unknown |
|        | 16q13      | Fractalkine | CXCL1 | T, NK |
|        |            | SCM-1β | XCL2     | T, NK     |
|        |            | XCR1   | XCL1     | T, NK     |
|        |            | CXCR1  | XCL1     | Mo, iDC, NK, Tc1, Th1 |

Figure 1 The chemokine system: an overview. Chemokines, their receptors, and predominant receptor repertoires in different leukocyte populations are listed. The selected ligands are identified with one old acronym and the new nomenclature, in which the first part of the name identifies the family and L stands for “ligand,” followed by a progressive number. Red identifies predominantly “inflammatory” or “inducible” chemokines; green, “homeostatic” agonists; yellow molecules belong to both realms. Chemokine acronyms are as follows: BCA, B-cell activating chemokine; BRAK, breast and kidney chemokine; CTACK, cutaneous T-cell-attracting chemokine; ELC, Epstein-Barr virus–induced receptor ligand chemokine; ENA-78, epithelial cell–derived neutrophil-activating factor (78 amino acids); GCP, granulocyte chemoattractant protein; GRO, growth-related oncogene; HCC, hemofiltrate CC chemokine; IP, interferon-inducible protein; I-TAC, interferon-inducible T-cell A chemotractant; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; Mig, monokine induced by γ interferon; MIP, macrophage inflammatory protein; MPIF, myeloid progenitor inhibitory factor; NAP, neutrophil-activating protein; PARC, pulmonary and activation-regulated chemokine; RANTES, regulated upon activation normal T cell–expressed and secreted; SCM, single C motif; SDF, stromal cell–derived factor; SLC, secondary lymphoid tissue chemokine; TARC, thymus and activation-related chemokine; TECK, thymus-expressed chemokine. Ba, basophils; CC, chemokine with the first 2 cysteines in adjacent positions; Eo, eosinophils; iDC, immature dendritic cells; MC, mast cells; mDCs, mature dendritic cells; Mo, monocytes; Mo, macrophages; NK, natural killer cells; PMN, neutrophils; T act, activated T cells; T naive, naive T cells; T muc, mucosal-homing T cells; T reg, regulatory T cells; T skin, skin-homing T cells.
The third chemokine subfamily includes 2 highly related molecules with only 2 cysteine residues (C chemokines), encoded by a single cluster on chromosome 1q23, selectively active on T lymphocytes. The fourth family (CX3C chemokines) include a single molecule with 3 intervening amino acids between the first 2 cysteine residues. This chemokine is coded by a gene located on 16q13 and acts on monocytes and T lymphocytes. Differently from all other chemokines, it has a transmembrane domain that allows it to be tethered to the cell surface.

The cysteine residue positions also dictate the new nomenclature for chemokines, based on the subclass followed by a number provided by the position of the corresponding coding gene in the cluster. Thus, chemokines now are identified by a name providing information on the respective structural subfamily, corresponding also to the type of receptor they engage, followed by a number provided by and referring to the respective coding gene (for the relationship between old and new nomenclatures, refer to Figure 1).

Chemokine receptors define a distinct subfamily in the rhodopsin-like G protein–coupled receptor family. At present, 18 receptors have been defined molecularly, 10 for CC chemokines (CCR1 to 10), 6 for CXC chemokines (CXCR1 to 6), and 1 for C chemokines and CX3C chemokines (XCR1 and CX3CR1, respectively). All chemokine receptors are single polypeptide chains spanning the membrane 7 times, with an acidic N-terminal extracellular domain and a serine-threonine–rich intracellular C-terminal domain. Two disulfide bonds between the N-terminal domain and the second extracellular loop and between the first and third extracellular loops normally are required for the definition of the molecular structure. In most cases, each individual receptor binds multiple chemokines, but subclass restriction is strictly respected. Thus, a major functional correlate of chemokine subclassification is represented by the use of different receptors whose names include the chemokine subclass specificity followed by a number.

Although distinct chemokines also exert several biologic functions, including regulation of hematopoiesis, fibrosis, and angiogenesis, they share a major (and eponymous) function represented by their ability to induce directional cell migration, thus coordinating leukocyte recruitment in physiologic and pathologic conditions (Figure 2). Leukocyte contact with endothelium might be transient, reversible, and activation-independent. In this phase, cells roll across the endothelial surface by chemokine-independent interactions of selectins with counteradhesins. At inflamed sites, the leukocyte enters a second phase involving chemokine receptor engagement by specific chemokines that are immobilized on the endothelial surface by proteoglycans. Chemokine receptor activation in turn activates β2 integrins, allowing leukocyte high-affinity binding to endothelial cell counterreceptors and subsequent extravasation (Figure 2). The simultaneous action of chemokines and integrins also is needed for full activation of leukocytes and, in synergy with primary cytokines, enhances phagocytosis, superoxide production, granule release, and bactericidal activity.

Chemokines act as intercellular signals, being produced under appropriate conditions by virtually every cell type and acting on several target cells, leukocytes in particular. Some chemokines are produced constitutively, but most

![Figure 2](image-url) Chemokine biologic functions. All chemokines share a common biologic property represented by leukocyte chemoattraction and recruitment during immune responses. Selected chemokines also exert other chemotaxis-independent biologic functions acting on nonleukocyte populations. Chemotaxis-dependent functions include the following: (1) leukocyte recruitment, including cell adhesion, integrin activation, and cell migration and (2) application of immune responses (innate and specific). Chemotaxis-independent functions include the following: (1) modulation of angiogenesis, (2) regulation of fibrosis, (3) proliferation and differentiation of hematopoietic precursors, (4) role in ontogeny (central nervous system and vasculature), (5) control of cell survival, and (6) gene expression regulation.
Chemokines must be induced (Figure 1). In general, proinflammatory cytokines such as tumor necrosis factor α, interleukin 1β, or interferon (IFN)-γ up-regulate inflammatory chemokines, whereas anti-inflammatory mediators, such as interleukin 10 and glucocorticoids, have an opposite effect.9 Most inducible chemokines are regulated at the transcriptional level, but some are stored for immediate release, as in the case of CXCL4 and CCL5 in platelet α granules. Chemokine receptors also are subjected to expression control. It is interesting that receptors for inflammatory chemokines usually are regulated opposite to the ligands, and several receptors are detected (or are functional) exclusively in specific cell states (eg CXCR3 on activated T cells).

Although narrow- and broad-spectrum chemokines exist, the spectra of action of different chemokines usually overlap widely, and collectively they span the entire leukocyte spectrum, presumably to provide flexibility and specificity in leukocyte trafficking. Neutrophil-targeted chemokines are found mainly in the CXC subfamily, whereas monocyte/macrophages, eosinophils, and basophils are attracted mainly by CC chemokines (Figure 1). Both CC and CXC subfamilies also contain T lymphocyte–specific members, and specific chemokine receptors mark T_{h}1 (CXCR3 and CCR5) vs T_{h}2 (CCR3 and CCR4) subsets Figure 3I. The chemokine system is characterized by a high level of pleiotropism, with a given chemokine acting on different leukocyte populations. The sensitivity to the same chemoattractant allows the coordinated recruitment of different but functionally related leukocyte populations in specific immune responses. The chemokine system also is characterized by considerable redundancy. Some monomorous signaling units exist, such as CXCL12 and CXCR4, but in general a given receptor, in particular inflammatory chemokine receptors, recognizes more than a single chemokine, and a given chemokine usually binds to more than one receptor. Redundancy provides the molecular basis for robustness of the system, with alternative recruitment circuits being available to guarantee the final outcome.10

Figure 3I Role of chemokine in polarized immune responses. During type I and type II immune responses, master cytokines represented by interferon (IFN)-γ and interleukin (IL)-4, respectively, regulate chemokine production by stromal and inflammatory cells. Chemokines then support selective recruitment of polarized T cells and specific type I and type II effector cells expressing distinct panels of chemokine receptors. CC, chemokine with the first 2 cysteines in adjacent positions; CCL, CC ligand; CCR, CC receptor; CXC, chemokine with the first 2 of 4 total cysteines separated by an intervening amino acid; CXCL, CXC ligand; CXCR, CXC receptor; Ba, basophils; Eo, eosinophils; MC, mast cells; Mø, macrophages; NK, natural killer cells.
The Chemokine System in Inflammatory and Infectious Diseases

Since the description of the first chemokine in 1977, an impressive amount of information has been accumulated, correlating the chemokine system with the pathogenesis of different human diseases Table I. One large group of disorders is represented by those with a prominent inflammatory component. A nonredundant role of CXCL8 in neutrophil-mediated inflammatory disease has been demonstrated by CXCL8 neutralization that results in almost complete protection from multiple inflammatory challenges, by genetic deletion of CXCR2 that causes defective neutrophil recruitment Table I, and more recently by pharmacologic inhibition of CXCR1.

Consistent with in vitro data, gene-targeted studies in mice also demonstrated the importance of CC inflammatory chemokines and respective receptors in monocyte recruitment. CCR1−/- and CCR2−/- mice present altered Schistosoma egg- or purified protein derivative–induced granulomatous inflammation that correlates with abnormal T1 and T2 cell responses (Table 2), CCR1−/- mice also have reduced pancreatitis-associated pulmonary infiltration, and CCR5−/- mice have enhanced delayed hypersensitivity reactions and increased humoral responses to T cell–dependent antigenic challenge (Table 2). Collectively, these results demonstrate a nonredundant role for inflammatory chemokines in leukocyte recruitment associated with acute and chronic inflammatory responses.

As predicted, studies with gene-targeted animals also have demonstrated a role for chemokines in host defense. For example, CXCR2−/- and CCR1−/- mice have increased susceptibility to inoculation with Aspergillus fumigatus, whereas CCR5−/- and CCR2−/- mice are more susceptible to infection with Listeria monocytogenes (Table 2). Similarly, CCL3−/- mice have markedly reduced coxsackie and influenza virus–induced inflammation of the heart and lung, respectively (Table 2).

Although chemokines and chemokine receptors probably evolved to coordinate leukocyte recruitment that supports an antimicrobial response, many have been exploited by infectious agents to facilitate infection. Two models of exploitation have been identified. In a first scenario, pathogens interfere with the chemokine system by producing chemokine-binding molecules that inhibit their biologic activities, such as the M3 protein secreted by herpesvirus 68, or by pirating chemokines or chemokine receptors and modifying them to generate antagonists or chemokine scavengers. Some pathogens produce multiple chemokine-related molecules affecting the host immune response in several ways. The Kaposi sarcoma–associated herpesvirus, also known as human herpesvirus 8, encodes a 7-transmembrane domain receptor known as open reading frame 74, highly related to the human CXCR2 but constitutively active (which exerts mitogenic and angiogenic activity in Kaposi sarcoma), and 3 chemokine–related molecules (v-macrophage inflammatory protein [MIP]I, MIPII and MIPIII) that act on CCR3 and CCR4 and support T122 recruitment, allowing tumors to escape the immune response.

A second mechanism used by intracellular pathogens is represented by exploitation of cellular receptors for cell entry. A first example of such a mechanism is represented by the malaria-causing protozoan Plasmodium vivax, which enters erythrocytes by using a chemokine promiscuous receptor called Duffy antigen receptor for chemokines. A second example is HIV-1, which gains access to immune cells using CD4 as a primary cellular receptor and a chemokine receptor, CXCR4 or CCR5, as strain-specific coreceptors. A variety of blocking agents, including agonists, antagonists, and antibodies, clearly have demonstrated a nonredundant role for CCR5 and CXCR4 in HIV infection. Moreover, a clear-cut role for CCR5 also has been demonstrated through the discovery that a mutant allele bearing a 32-base-pair deletion in the open reading frame (CCR5-∆32), which encodes a truncated and inactive

### Table I

Chemokines and Chemokine Receptors Associated With Major Human Diseases*  

| Type              | Diseases                                      | Chemokines and Chemokine Receptors Involved |
|-------------------|-----------------------------------------------|---------------------------------------------|
| Inflammatory      | Arthritis; colitis                            | Inflammatory CC and CXC                     |
| Infectious        | Several acute and chronic bacterial and viral infections; sepsis | CXCR4 and CCR5; inflammatory CC and CXC |
| Autoimmune        | Rheumatoid arthritis; systemic lupus erythematosus; multiple sclerosis | Inflammatory CC |
| Allergic          | Asthma                                        | CCL1 and CCR3, CCL2 and CCR4, CCL1 and CCR8 |
| Neoplasia         | Metastasis; angiogenesis                      | CCL12 and CXCR4, CCL19 and CCR7            |
| Graft rejection   | Heart allograft                               | CCL5, CCL2, CCL3 and CCR5                  |
| Vascular          | Atherosclerosis; ischemia-reperfusion         | CCL8 and CXCR1                             |
|                   |                                               | CXCL9, CXCL10, CXCL11 and CXCR3             |
|                   |                                               | CCL2 and CCR2, CXC3CL1 and CXC3R           |

* Principal human diseases associated with different chemokines and their receptors are listed. Correlations are supported by data referring to chemokine detection (see text), animal models (detailed in Table 2), and genetic evidence (detailed in Table 3).
Chemokine Receptor Gene-Targeted Animals

| Receptor | Phenotype | Insight |
|----------|-----------|---------|
| CXCR2    | Defective recruitment of neutrophils; increased sensitivity to Toxoplasma; increased sensitivity to urinary tract infections; abnormal wound healing; reduced progression of atherosclerotic plaques | Host defense; innate immunity; graft rejection (acute); atherogenesis |
| CXCR3    | Reduction in acute allograft rejection | Graft rejection (chronic) |
| CXCR4    | Embryo, lethal defect; defective development in cardiovascular, central nervous, and hematopoietic systems | Embryogenesis |
| CXCR5    | Abnormalities in lymph nodes and Peyer patch development | Lymphoid organogenesis |
| CCR1     | Imbalance of T1/T2 cytokines; defective granuloma formation; reduction in acute allograft rejection; resistance to experimental autoimmune encephalitis; reduced pancreatitis-associated lung injury; increased nephritis-associated glomerular injury; increased sensitivity to Toxoplasma and Aspergillus | Host defense; innate immunity; graft rejection (acute); adaptive immunity; autoimmunity; atherogenesis |
| CCR2     | Defective recruitment of macrophages; defective production of T1 cytokines; increased sensitivity to Listeria; Aspergillus; normal susceptibility to Leishmania; reduction in acute allograft rejection; resistance to experimental autoimmune encephalitis; reduced progression of atherosclerotic plaques | Host defense; innate immunity; graft rejection (acute); autoimmunity; atherogenesis |
| CCR3     | Reduced eosinophil recruitment, but increased bronchoconstriction in airway allergic models; reduced eosinophil recruitment but normal basophil and IL-4 concentrations in skin allergic diseases | Type II immune response |
| CCR4     | No effect in T2-dependent airway inflammation; resistance to LPS-induced endotoxic shock | No role in type II immune response; innate immunity; no role in antiviral immunity |
| CCR5     | Enhanced DTH reactions; increased sensitivity to Listeria and Cryptococcus; reduced macrophage infiltration and demyelination; normal sensitivity to experimental autoimmune encephalitis; normal immune response to choriomeningitis virus | Mucosal immune responses; type II immune response |
| CCR6     | Defective homing of dendritic cells in Peyer patches; impaired humoral response to orally administered antigens; increased inflammation in contact hypersensitivity; reduced DTH reactions; reduced of eosinophil recruitment, airway resistance, IL-5 and IL-13 levels in airway allergic models | Lymphoid organogenesis; adaptive immunity |
| CCR7     | Abnormalities in lymph nodes and Peyer patch development; defective lymph node homing of dendritic cells; reduced contact hypersensitivity; reduced DTH reactions | Type II immune response |
| CCR8     | T2 normal development, but aberrant cytokine production; defective immune response to Schistosoma eggs; normal immune response to Mycobacterium; reduced eosinophil recruitment in airways allergic models | Type II immune response |
| CCR9     | Reduced intraepithelial homing of γδ+ T cells | Mucosal immunity |
| CX3CR1   | Defective NK cell recruitment; reduced allograft rejection in immunosuppressed conditions; normal susceptibility to experimental autoimmune encephalitis; normal antibody-induced glomerulonephritis; possible role in atherosclerosis | Type I immune response |

**Phenotypic Abnormalities in Chemokine Receptor Gene-Targeted Animals**

| Receptor | Allelic Variant | Functional Effect | Clinical Correlation |
|----------|-----------------|-------------------|----------------------|
| CCR5     | CCR5-Δ32        | 32-bp deletion in ORF (null allele) | Resistance to HIV infection; improved kidney allograft survival; reduced relapse rate in multiple sclerosis |
| CCR5     | M303            | Protein truncation | Resistance to HIV infection |
| CCL5     | −28G            | Promoter SNP      | Prolonged survival in patients with AIDS |
| CXC12    | −3A             | 3'-UTR SNP        | Prolonged survival in patients with AIDS |
| CCR2     | V64I            | Protein point mutation | Prolonged survival in patients with AIDS |

**Allelic Variants of Chemokines or Chemokine Receptors Associated With Altered Disease Susceptibility or Progression in Humans**

bp, base pairs; CC, chemokine with the first 2 cysteines in adjacent positions; CCL, CC ligand; CCR, CC receptor; CXC, chemokine with the first 2 or 4 total cysteines separated by an intervening amino acid; CXCR, CXC receptor; IL, interleukin; LPS, lipopolysaccharide; NK, natural killer.

**Role of the Chemokine System in Autoimmune Diseases**

Leukocyte recruitment, accumulation, and activation are common events in autoimmune disorders. The use of potent and cytotoxic immunosuppressive therapies for the treatment of these diseases reflects limited understanding of...
the mechanisms that allow leukocytes to be recruited and sustain the chronic inflammatory reaction characteristic of autoimmune diseases. The importance of chemokines and chemokine receptors in the pathogenesis of autoimmunity was suggested initially by a number of animal models (Table 2) and has been confirmed by genetic evidence and clinical studies (Table 3).

In animal models of multiple sclerosis (MS), experimental autoimmune encephalomyelitis, and rheumatoid arthritis (RA), chemokine levels correlate with disease progression,65,66 and the treatment of affected mice with chemokine antagonists or blocking antibodies has provided the first proof of the concept attesting the involvement of chemokines in autoimmune diseases.67 The study of gene-targeted mice has revealed that the absence of a chemokine or its receptor might prevent or attenuate the insurgence of autoimmune diseases. For example, the absence of CCR1 and CCR2 is protective in experimental autoimmune encephalomyelitis,67 and CCL3 deficiency in nonobese diabetic mice is protective for induced insulitis and spontaneous diabetes.68

Consistent with results obtained in animal models, clinical studies have demonstrated that chemokine and chemokine receptor expression is significantly altered during the evolution of certain autoimmune diseases. In patients with RA, clinical disease activity correlates with CCL2 and CCL5 levels,69 which have been proposed as markers of disease activity. Moreover, methotrexate treatment of patients with RA correlates with a reduction of CCL5 levels.70 Similarly, elevated serum levels of CXCL10 have been associated with clinical disease activity in systemic lupus erythematosus.71 Elevated levels of inflammatory CC chemokines (CCL3, CCL4, and CCL5, in particular) and their receptors (CCR2, CCR3, and CCR5) also have been found in the central nervous system of patients with MS,72,73 and T cells from patients with MS treated with IFN-β showed reduced CCR5 expression and migration in response to CCL5 and CCL3.74 A relevant role of CCR5 in T-cell recruitment to brain lesions correlates with genetic evidence showing that patients with MS with the CCR5-Δ32 allelic variant are not protected in the initial phase of the disease but have a lower risk of recurrent clinical disease69 (Table 3).

Taken together, these observations make the chemokine system a potential target for the clinical management of autoimmune diseases. Indeed, several pharmaceutical companies are actively involved in the identification of small molecule receptor antagonists acting on chemokine receptors Table 4. The complexity of the chemokine system, however, imposes a need to clarify the role of specific chemokines in specific autoimmune disorders to understand which molecules are the best targets for each disease.

Role of Chemokines in Allergic Diseases

Allergic inflammation is a T<sub>h</sub><sub>2</sub> disease associated with the selective recruitment of eosinophils and allergen-specific T<sub>h</sub><sub>2</sub> lymphocytes. Selective expression of chemokine receptors on these leukocytes has been postulated to be the mechanism by which they are recruited selectively to the allergic site.75

In vitro and in vivo studies have provided evidence that CCR3, CCR4 and CCR8 are involved in the recruitment of T<sub>h</sub><sub>2</sub> lymphocytes.76 Mouse models with blocking antibodies against CCR3 and CCR4 ligands (CCL11, CCL22, and CCL17) show decreased airway inflammation and airway hyperresponsiveness,77-79 whereas neutralization of the CCR8 ligand (CCL1) has no effect on the recruitment of T<sub>h</sub><sub>2</sub> cells in the lung.80 However, genetically modified animals do not confirm in vivo data obtained with inhibitors. CCR3+/− mice have reduced eosinophil recruitment to the lung after allergen challenge but increased airway hyperresponsiveness.35 CCR4−/− mice show no protection against the development of allergic inflammation,37 and 2 of 3 studies reported no effect of CCR8 deficiency on the development of allergen-driven airway inflammation.81 The number of CCR4+ and CCR8+ T cells in human lung biopsy specimens is increased after allergen challenge, whereas CCR3+ cells are not detected. Moreover, CCL22 and CCL17 levels are increased after allergen challenge, but CCL1 and CCL11 expression are not detected.82,83 Thus, several indications suggest a role for chemokines in allergic diseases, but a clear definition of the specific role of different molecules is still missing.

Role of Chemokines in Neoplastic Diseases

Chemokines and chemokine receptors have been found in almost all tumors, and the composition of the tumor infiltrate is related to tumor and stromal cell production of...
Chemokines. In vitro and in vivo experiments suggest that the chemokine CCL2 can suppress tumor growth, inducing a dense mononuclear infiltrate.\(^8\) Moreover, it has been demonstrated that the same chemokine is able to act as an adjuvant to enhance T cell–dependent host antitumor response.\(^8\) However, most clinical and epidemiologic studies suggest that chemokine expression might be advantageous for the tumor. In patients with ovarian and breast cancer, chemokine levels (CCL2 and CCL5) correlate with macrophage infiltration, lymph node metastasis, and clinical aggressiveness.\(^6\) In contrast, high serum levels of CCL2 in patients with pancreatic cancer correlate with macrophage infiltration and good prognosis.\(^7\)

Chemokines also might help the tumor to subvert the immune system by the polarization of the immune response to a Th2 type to suppress specific anticancer responses. Examples are provided by Hodgkin lymphoma in which there is a prominent production of T\(_\text{h}2\), chemokines by Reed-Sternberg cells\(^8\) and by human herpes virus 8 that encodes 3 viral chemokines (v-MIPI, v-MIPII, and v-MIPIII) that selectively attract T\(_\text{h}2\) lymphocytes, as described in the preceding text.

Cancer cells not only produce high amount of chemokines, but also express some functional chemokine receptors. CXCR4 seems to be expressed by the majority of cancer cells, including breast, prostate, pancreatic, lung, and ovarian carcinomas.\(^0\) CCR7 is expressed by gastric and esophageal carcinoma cells and by melanoma cells.\(^1\) Experimental murine cancer models provide some proof that cancer cells might use chemokine receptors to migrate to metastatic sites where their ligands are overexpressed.\(^1\) Moreover, data from 600 patients with prostate cancer revealed that CXCR4 protein expression was higher in localized and metastatic prostate cancer than in normal or benign prostate tissue.\(^2\)

Chemokines also might act as growth and survival factors in an autocrine and/or a paracrine manner. For example, melanoma cells express high levels of the receptor CXCR2 and also constitutively produce the chemokines CXCL1 and CXCL8 that stimulate, in an autocrine way, proliferation and survival.\(^3\) Similarly, prostate cancer cells and glioblastoma cells express CXCR4 and CXCL12 stimulate their proliferation.\(^2\)

Chemokines might regulate angiogenesis within the primary and metastatic tumors. ELR+ CXC chemokines and some CC chemokines promote angiogenesis, whereas ELR–CXC chemokines are antiangiogenic. CXCL10 levels in lung cancers are inversely related to tumor progression,\(^4\) and CXCL5 levels in no–small cell lung cancer are correlated with the vascularity of the tumor and angiogenesis.\(^5\) Although no evidence exists about their involvement in cancer pathogenesis, it is likely that chemokines will have important effects in cancer pathobiology because they affect different activities that impact cancer, such as leukocyte infiltration, metastatic potential, tumor growth, and angiogenesis.\(^6\-\text{7}\)

**Role of Chemokines in Transplant Rejection**

Chemokine effects on inflammatory and immune responses not surprisingly influence several aspects of allograft biology.\(^8\) Allograft analysis at different time points after transplantation indicates that 2 chemokine cascades are activated.\(^9\) A first set of events takes place in the hours and days after allograft surgery, and the events are associated with trauma and ischemia–reperfusion graft damage. This acute reaction involves local production of proinflammatory cytokines, vascular endothelium activation, and chemokine production. In an early phase, ELR+ CXC chemokines dominate and have a central role in neutrophil recruitment and subsequent ischemia–reperfusion–dependent tissue damage. Experimental approaches based on blocking antibodies,\(^1\) gene-targeted mice (Table 2), and pharmacologic inhibition of chemokine receptors (Table 4) have demonstrated that attenuation of neutrophil infiltration by interfering with ELR+ CXC chemokines significantly reduces tissue damage and preserves organ function. Subsequently, inflammatory CC chemokines directed at mononuclear cells, such as CCL2, CCL3, and CCL4, also are produced, although at considerably lower levels.\(^1\) Consistent with these observations, blocking antibodies to inflammatory CC chemokines\(^1\) and targeted deletion of their respective receptors CCR1, CCR2, or CCR5 suppresses acute allograft rejection (Table 2).

After resolution of the initial inflammatory phase, a delayed reaction associated with the infiltration of alloantigen-specific T lymphocytes takes place. This second phase is controlled mainly by the T cell–specific ELR–CXC chemokines CXCL9, CXCL10, and CXCL11, induced by local production in the allograft of IFN-\(\gamma\).\(^1\) The importance of this group of chemokines has been demonstrated by the protective effect of blocking antibodies\(^1\) and by the extended allograft survival in CXCR3–/– mice (Table 2). It is interesting to note that the infiltration of effector CD8+ T cells, responsible for the type I polarization of the immune response with IFN-\(\gamma\) production and consequent induction of CXCR3 agonists (Figure 3), requires the phagocyte–dependent acute phase.\(^9\) This indicates that therapeutic intervention focusing not only on chemokines responsible for recruitment of final effectors (CXCR3-dependent), but also on chemoattractants involved in the acute reaction (mainly dependent on inflammatory CC and ELR+ CXC...
chemokines), could result in prolonged allograft survival, especially if used in conjunction with subtherapeutic doses of immunosuppressive agents.\textsuperscript{19,49,104} Chemokine receptor antagonists targeting CXCR1, CXCR3, CCR1, and CCR5 are under development (Table 4).

The importance of chemokines and their receptors in allograft rejection has taken on greater importance because of new genetic (Table 3) and clinical studies. Expression levels of CXCL10 and its receptor CXCRII in endomyocardial, lung, and liver biopsy specimens of transplanted organs correlates with ongoing acute allograft rejection.\textsuperscript{105,106} Similarly, in renal transplants, inflammatory CC chemokines and ELR–CXC chemokines have been detected during rejection episodes,\textsuperscript{107,108} and their levels correlate with the histologic grade of rejection,\textsuperscript{109} suggesting a relationship between type and level of chemokines locally produced, leukocyte infiltration, and allograft evolution. Although the number of studies is limited, existing data indicate that the presence of specific chemokines and their receptors is predictive of increased risk for acute or chronic allograft rejection.

Chemokines also might have a role in 2 aspects of major relevance in the management of transplant recipients, ie, host responses to opportunistic infectious agents (see earlier text) and allograft-accelerated arteriosclerosis (see subsequent text).

### Role of Chemokines in Vascular Diseases

Atherosclerotic plaques are thought to result from an inflammatory response to arterial damage.\textsuperscript{110} Chemokines are involved in this process, at first because they can mediate monocyte adhesion to the vascular endothelium and migration to subendothelium (where they become the foam cells originating fatty streaks) and later by activating macrophages and promoting migration of smooth muscle cells into the intima. Chemokines also might influence thrombus formation over the plaque.\textsuperscript{111,112} Animal models of atherosclerosis have revealed a role for many chemokines, including CXCL8, CXCL12, CXCL10, and CCL1.\textsuperscript{18,113-115}

CCL2–/– and CCR2–/– mice have 65% to 85% less arterial lipid deposition than normal mice in hypercholesterolemia models. Disease reduction is correlated with a decrease of macrophages in the arterial wall, suggesting that CCL2 might attract CCR2-bearing monocytes in the vessel wall.\textsuperscript{29,116} Moreover, proof of the concept of the role of CCL2 and CCR2 in this disease derives from the use of a CCL2 antagonist that prevents monocyte recruitment in a coronary artery remodeling system.\textsuperscript{117}

CX3CR1–/– mice also are protected against diet-induced atherosclerosis.\textsuperscript{118,119} It has been reported that a polymorphic variant of this receptor (V280) correlates with protection from coronary artery disease in humans.\textsuperscript{50,120} The relevance of the chemokine system in the human disease also is supported by data from human lesions, as several chemokines, including CCL2, CCL5, CCL3, CCL11, and CX3CL1, have been detected within atherosclerotic plaques.\textsuperscript{121,122} Moreover, clinical data reveal that members of the statin family inhibit expression of CCL2,\textsuperscript{123} suggesting that these molecules reduce atherosclerotic risk in part by inhibiting expression of inflammatory chemokines and the consequent recruitment of macrophages in the arterial wall.

### Chemokines and Their Clinical Uses

Although the role of chemokines and their receptors in the pathogenesis of different human diseases has been evaluated extensively in the scientific literature (and summarized briefly herein), the possible relevance of chemokines and their receptors as biomarkers has been evaluated in a limited number of diseases.\textsuperscript{124} Significant alterations in chemokine profiles have been highlighted in a number of clinical studies, but a convincing indication that chemokine determination could be applied to the diagnosis or the monitoring of most diseases is still missing.

In general, determination of chemokines and their receptors has been proven useful for monitoring disease activity and predicting relapses,\textsuperscript{125} monitoring the efficacy of surgical and pharmacological therapies,\textsuperscript{126} and providing prognostic indications.\textsuperscript{127} However, it also is important to realize that chemokines and their receptors have some significant theoretical limitations as potential biomarkers.

Chemokines are rarely organ-specific and almost never specific to a particular disease, and their pleiotropic and redundant activity translates to a very similar pattern of changes in different clinical circumstances. Therefore, chemokines and their receptors are not likely to be ideal biomarkers for the diagnosis of or screening for diseases. In this context, it is of interest to note that none of the chemokine–chemokine receptor gene-targeted mice demonstrated increased susceptibility to spontaneous infections, consistent with the idea that sufficient redundancy exists within the system for baseline host defense. On the other hand, in vivo results in gene-targeted animals exposed to specific pathogens surprisingly indicated a nonredundant role of individual chemokines in specific diseases. Therefore, spatial and temporal regulation might be more functionally significant than would be expected by extrapolating from in vitro results and suggest a role for chemokines in modulating other aspects of the inflammatory response beyond simple leukocyte recruitment (Figure 2), including cross-talk with primary inflammatory and immune cytokines.\textsuperscript{10,128} (Figure 3).
Thus, emerging data indicate that the high level of redundancy suggested by in vitro studies might not be so relevant in vivo and should not diminish the interest for the evaluation of distinct chemokine–chemokine receptor systems in specific clinical conditions. The specificity that certain chemokines seem to demonstrate in the amplification of specific inflammatory responses is providing the rational for new therapeutic antichemokine approaches (Table 4).

**Measurement of Chemokines in Body Fluids and Tissues**

Among the numerous chemokines identified, only a limited number of chemokines is measured in clinical laboratory practice.1,129 Nevertheless, technological progress during the last 20 years has generated a large series of analytic approaches that are being implemented in routine clinical laboratories Table 5. Immunoassays have been introduced rapidly in clinical practice for chemokine measurement in biologic fluids. Their specificity is high owing to the use of monoclonal antibodies. The detection limit is highly dependent on the quality of the capture monoclonal antibody, but in general these assays have high sensitivity, with the evaluation limit of around 10 pg/mL for most chemokine test kits.

The advantages of immunoassays are their excellent reproducibility (coefficient of variation, 5%-10%) and their ease of use.130,131 Special attention must be given to the sampling and storage of biologic fluids, the major risks being the degradation of chemokines during storage and the cellular production or release of chemokines after sampling. Plasma or serum can both be used, and the samples are to be stored deep-frozen.

ELISPOT represents an interesting approach to determine the number of chemokine-producing cells in a heterogeneous population. In this assay, a stimulated cell suspension is laid on a microplate well coated with antibodies directed against the chemokine of interest.131 ELISPOT is more sensitive than classic enzyme-linked immunosorbent assays, allowing for the detection of as few as 3 chemokine-secreting cells per 10⁵ total cells. Moreover, because of its sensitivity, ELISPOT can be used to detect circulating chemokine-producing cells without in vitro stimulation. A biochip array technology based on a sandwich chemiluminescent immunoassay also has been developed, allowing for the simultaneous quantitative detection of multiple cytokines and chemokines in a single patient sample.

The local and paracrine activity of chemokines explains their low circulating levels and constitutes a strong limitation in the interpretation of their concentrations in body fluids. The tissue distribution can be studied at the protein or messenger RNA level (Table 5). Immunohistochemical analysis allows detection of chemokines or their receptors within tissues.132 Three successive steps (cell fixation, cell

| Table 5 |

| **Principal Methods for Chemokine Detection and Measurement** |
|----------------|------------------|-------------------|-----------------------|
| **Method** | **Target Molecule** | **Sample** | **Advantages** | **Limitations** |
| ELISA | Protein | Cell culture supernatant, cell lysate, serum, other biologic fluids | Highly specific and sensitive; rapid; adequate for high-throughput screening | Requires specific MoAb; high costs |
| IRMA | Protein | Cell culture supernatant, cell lysate, serum, other biologic fluids | Highly sensitive | Time-consuming, high cost, not adequate for high-throughput screening |
| Biochip array | Protein | Cell culture supernatant, cell lysate, serum, other biologic fluids | Simultaneous quantitative detection from a single sample | High costs |
| ELISPOT | Protein | Cell culture supernatant, cell lysate, serum, other biologic fluids | Highly specific and sensitive; provide indication of the cell source | Time-consuming; limited panel of molecules detectable |
| Immunohistochemical analysis | Protein | Tissues and cells | Provide indication of the cell source; allow for multiple labeling | Requires specific MoAb; time-consuming; not adequate for high-throughput screening |
| Flow cytometry | Protein | Cells | Adequate for high-throughput screening | Requires specific MoAb; high costs |
| In situ hybridization | mRNA | Tissues and cells | Does not require specific MoAb (complementary to immunohistochemical analysis) | Time-consuming; high costs |
| RT-PCR | mRNA | Tissues and cells | Possible for simultaneous detection of multiple compounds; adequate for high-throughput screening | Semiquantitative |
| DNA/oligo array | mRNA | Tissues and cells | Innovative application; simultaneous quantitative detection from a single sample | High costs |

ELISA, enzyme-linked immunosorbent assay; IRMA, immunoradiometric assay; MoAb, monoclonal antibody; mRNA, messenger RNA; RT-PCR, reverse transcriptase–polymerase chain reaction.
permeabilization, cytokine visualization using a specific antibody) are followed by a final visualization step, based on immunofluorescent or immunoenzymatic techniques. The possibility to combine double or triple labeling allows the identification of the phenotype of chemokine-producing cells. Recently, the detection of intracellular chemokines by flow cytometry also has been reported. Detection in tissue specimens or cell suspensions of chemokine messenger RNA by in situ hybridization also allows the identification of cells directly involved in chemokine synthesis among a heterogeneous population. Although it is time-consuming and expensive, this method does not require specific antibodies and, therefore, can be considered complementary to immunohistochemical analysis.

**Conclusion**

An impressive amount of information has linked the most common human diseases to chemokines. Although in vitro this complex system is characterized by an important degree of redundancy, data obtained with gene-targeted animals indicate that in vivo specificity for selected disorders might exist. The chemokine system also is characterized by a significant and, at present, only marginally defined degree of genetic variance in the general population, with significant effects on disease susceptibility and prognosis. A number of methodological approaches are available for specific and sensitive determination of chemokines, in biologic fluids and in tissues, and some of these methods are adequate for high-throughput applications. Thus, although clinical laboratory use of chemokines as biomarkers is limited, the time is ready to design clinical trials to specifically assess the impact of individual chemokine determinations on clinical decisions in specific diseases.

**References**

1. Bienvenu J, Monneret G, Fabien N, et al. The clinical usefulness of the measurement of cytokines. Clin Chem Lab Med. 2000;38:267-285.

2. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217-242.

3. Mantovani A, Sozzani S. Chemokines. Balkwill F, ed. The Cytokine Network. Oxford, England: Oxford University Press; 2000:103-125.

4. Rollins BJ. Chemokines. Blood. 1997;90:909-928.

5. Murphy PM, Baggioili M, Charo IF, et al. International union of pharmacology, XXII: nomenclature for chemokine receptors. Pharmacol Rev. 2000;52:145-176.

6. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 2001;12:313-335.

7. Murphy PM. The molecular biology of leukocyte chemo-attractant receptors. Annu Rev Immunol. 1994;12:593-633.

8. Mackay CR. Chemokines: immunology’s high impact factors. Nat Immunol. 2001;2:95-101.

9. Mantovani A, Locati M, Allavena P, et al. The chemokine superfamily: crosstalk with the IL-1 system. Immunobiology. 1996;195:522-549.

10. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today. 1999;20:254-257.

11. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-443.

12. Furie MB, Randolph GJ. Chemokines and tissue injury. Am J Pathol. 1995;146:1287-1301.

13. Harada A, Sekido N, Akahoshi T, et al. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol. 1994;56:539-564.

14. Cacalano G, Lee J, Kikly K, et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science. 1994;265:682-684.

15. Del Rio L, Bennousa S, Salinas J, et al. CXCR2 deficiency confers impaired neutrophil recruitment and increased susceptibility during Toxoplasma gondii infection. J Immunol. 2001;167:6503-6509.

16. Frendeus B, Godaly G, Hang L, et al. Interleukin-8 receptor deficiency confers susceptibility to acute pyelonephritis. J Infect Dis. 2001;183(suppl 1):S56-S60.

17. Devalaraja RM, Nanney LB, Du J, et al. Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol. 2000;115:234-244.

18. Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 receptor CXCR2 in atherosclerosis. Immunol Res. 2000;21:129-137.

19. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med. 2000;192:1515-1520.

20. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591-594.

21. Forster R, Mattis AE, Kremmer E, et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 1996;87:1037-1047.

22. Gao JL, Wynn TA, Chang Y, et al. Impaired host defense, hematopoesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med. 1997;185:1959-1968.

23. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCRI suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest. 2000;105:35-44.

24. Rottman JB, Slavin AJ, Silva R, et al. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCRI dependent. Eur J Immunol. 2000;30:2372-2377.
25. Gerard C, Frossard JL, Bhatia M, et al. Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. J Clin Invest. 1997;100:2022-2027.

26. Topham PS, Czitromida V, Soler D, et al. Lack of chemokine receptor CCR1 enhances T1 responses and glomerular injury during nephropathic nephritis. J Clin Invest. 1999;104:1549-1557.

27. Khan IA, Murphy PM, Casciotti L, et al. Mice lacking the chemokine receptor CCR1 show increased susceptibility to Toxoplasma gondii infection. J Immunol. 2001;166:1930-1937.

28. Bleak L, Mehnd B, Standiford TJ, et al. Airway remodeling is absent in CCR1—/- mice during chronic fungal allergic airway disease. J Immunol. 2000;165:1564-1572.

29. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2—/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.

30. Kuribara T, Warr G, Loy J, et al. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med. 1997;186:1757-1762.

31. Bleak L, Mehnd B, Standiford TJ, et al. Enhanced pulmonary allergic responses to Aspergillus in CCR2—/- mice. J Immunol. 2000;165:2603-2611.

32. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001;108:547-556.

33. Fife BT, Huffnagle GB, Kuziel WA, et al. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med. 2000;192:899-905.

34. Peters W, Charo IF. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol. 2001;12:175-180.

35. Humbles AA, Lu B, Friend DS, et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci U S A. 2002;99:1479-1484.

36. Ma W, Bryce PJ, Humbles AA, et al. CCR3 is essential for skin eosinophilia and airway hyperresponsiveness in a murine model of allergic skin inflammation. J Clin Invest. 2002;109:621-628.

37. Chvatchko Y, Hoogewerf AJ, Meyer A, et al. A key role for the CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med. 2000;191:1755-1764.

38. Zhou Y, Kuribara T, Ryseck RP, et al. Impaired macrophage function and enhanced T cell–dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol. 1998;160:4051-4058.

39. Huffnagle GB, McNeil LE, McDonald RA, et al. Cutting edge: role of C-C chemokine receptor 5 in organ-specific and bone marrow–derived dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 2000;12:495-503.

40. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1 alpha or its CCR5 receptor. Eur J Immunol. 2000;30:1410-1415.

41. Nansen A, Christensen JP, Andersen SO, et al. The role of CC chemokine receptor 5 in antiviral immunity. Blood. 2002;99:1237-1245.

42. Cook DN, Proser DM, Forscher R, et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity. 2000;12:495-503.

43. Vicia R, Villares R, Caramolino L, et al. CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. J Clin Invest. 2001;107:R37-R45.

44. Luks NA, Proser DM, Wiekowski M, et al. Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J Exp Med. 2001;194:551-555.

45. Forscher R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999;99:23-33.

46. Chensue SW, Lukacs NW, Yang TY, et al. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med. 2001;193:573-584.

47. Wurbel MA, Malissen M, Guay-Grand D, et al. Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor β+ gut intraepithelial lymphocytes. Blood. 2001;98:2626-2632.

48. Bais C, Santamasso B, Coso O, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 2001;97:1925-1928.

49. Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004;101:11791-11796.

50. Murphy FM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol. 2001;2:116-122.

51. Bais C, Santamasso B, Coso O, et al. G-protein–coupled receptor of Kaposi’s sarcoma–associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86-89.

52. Endres MJ, Garlisi CG, Xiao H, et al. The Kaposi’s sarcoma–associated herpesvirus–encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor CCR3. J Exp Med. 1999;189:1993-1998.

53. Berger EA, Murphy PM, Farber JM. Chemokine receptors as targets for HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.

54. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.

55. O’Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32 [letter]. Lancet. 1997;349:1219.

56. Fischinger M, Luckow B, Hocher B, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol. 1998;25:1462-1465.
60. Lu Z, Berson JF, Chen Y, et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci U S A. 1997;94:6426-6431.

61. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression: Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866-870.

62. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A. 1999;96:4518-4585.

63. Winkler C, Modit W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant: ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389-393.

64. Michael NL, Louie LG, Rohrbaugh AL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med. 1997;3:1160-1162.

65. Thornton S, Duwel LE, Boivin GP, et al. Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. 1999;42:1109-1118.

66. Karpus WJ, Ransohoff RM. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol. 1998;161:2667-2671.

67. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol. 2002;2:106-115.

68. Cameron MJ, Arreaza GA, Gnutta M, et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type 1 diabetes. J Immunol. 2000;165:1102-1110.

69. Ellingsen T, Baus A, Stengard-Pedersen K. Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis. J Rheumatol. 2001;28:41-46.

70. Boiardi L, Macchioni P, Meliconi R, et al. Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol. 1999;17:419-425.

71. Narumi S, Takeuchi T, Kobayashi Y, et al. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000;12:1561-1565.

72. Bowen LA, Montague L, Nottet HS, et al. Macrophage inflammatory protein-1 alpha (MIP-1 alpha), MIP-1 beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin Exp Immunol. 2000;122:257-263.

73. Simpson J, Rezaie P, Newcombe J, et al. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol. 2000;108:192-200.

74. Zang YC, Halder JB, Samanta AK, et al. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1 alpha by interferon-beta. J Neuroimmunol. 2001;112:174-180.

75. Lloyd CM, Rankin SM. Chemokines in allergic disease. Curr Opin Pharmacol. 2003;3:443-448.

76. Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non–small cell lung cancer. J Clin Invest. 1998;102:465-472.

77. Gonzalez JA, Lloyd CM, Wen D, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med. 1998;188:157-167.

78. Gonzalez JA, Pan Y, Lloyd CM, et al. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. J Immunol. 1999;163:403-411.

79. Kawasaki S, Takizawa H, Yoneyama H, et al. Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J Immunol. 2001;166:2055-2062.

80. Bishop B, Lloyd CM. CC chemokine ligand 1 promotes recruitment of eosinophils but not T2 cells during the development of allergic airways disease. J Immunol. 2003;170:4810-4817.

81. Chung CD, Kuo F, Kumer J, et al. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. J Immunol. 2003;170:581-587.

82. Panina-Bordignon P, Papi A, Mariani M, et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest. 2001;107:1357-1364.

83. Nouri-Aria KT, Wilson D, Francis JN, et al. CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol. 2002;32:1933-1938.

84. Walter S, Bottazzi B, Govoni D, et al. Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocytic chemotactic protein/JE. Int J Cancer. 1999;49:431-435.

85. Manome Y, Wen PY, Henshowitz A, et al. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother. 1995;41:227-235.

86. Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999;59:4681-4687.

87. Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res. 2003;63:7451-7461.

88. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283-4297.

89. Sozzani S, Luini W, Bianchi G, et al. The viral chemokine monocyte chemotactic protein/JE. Cytokine. 2001;12:1561-1565.

90. Bogunia-Kubik K, Kaczmarek L, Wlodarska KA, et al. The coordinated action of RANTES, eotaxin, and growth of sarcoma clones expressing different amounts of monocytic chemotactic protein/JE. Int J Cancer. 2000;86:394-402.

91. Muller A, Honey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.

92. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89:462-473.

93. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol. 2002;72:9-18.

94. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1-8.

95. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14:171-179.

96. Muller A, Honey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
96. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. *Semin Cancer Biol.* 2004;14:149-154.

97. Kulbe H, Levinson NR, Balkwill F, et al. The chemokine network in cancer: much more than directing cell movement. *Int J Dev Biol.* 2004;48:489-496.

98. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. *Curr Opin Immunol.* 2002;14:562-568.

99. Morita K, Miura M, Paolone DR, et al. Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. *J Immunol.* 2001;167:2979-2984.

100. Miura M, Fu X, Zhang QW, et al. Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. *Am J Pathol.* 2001;158:2137-2145.

101. Yun JJ, Fischbein MP, Laks H, et al. RANTES production during development of cardiac allograft vasculopathy. *Transplantation.* 2001;71:1649-1656.

102. Miura M, Morita K, Kobayashi H, et al. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. *J Immunol.* 2001;167:3494-3504.

103. Zhang Z, Kaptanoglu L, Haddad W, et al. Donor T cell activation initiates small bowel allograft rejection through an IFN-gamma-inducible protein-10-dependent mechanism. *J Immunol.* 2002;168:3205-3212.

104. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. *Transplantation.* 2001;72:1199-1205.

105. Melter M, Exeni A, Reinders ME, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human renal transplant rejection. *Circulation.* 2001;104:2558-2564.

106. Agostini C, Calabrese F, Rea F, et al. Cxcr3 and its ligand CX3CL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. *Am J Pathol.* 2001;158:1703-1711.

107. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. *Am J Kidney Dis.* 2001;37:518-531.

108. Cockwell P, Chakravorty SJ, Girdlestone J, et al. Fractalkine expression in human renal inflammation. *J Pathol.* 2002;196:85-90.

109. Robertson H, Morley AR, Talbot D, et al. Renal allograft rejection: beta-chemokine involvement in the development of tubulitis. *Transplantation.* 2000;69:684-687.

110. Libby P. Inflammation in atherosclerosis. *Nature.* 2002;420:868-874.

111. Gerard C, Rollins BJ. Chemokines and disease. *Nat Immunol.* 2001;2:108-115.

112. Chao IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. *Circ Res.* 2004;95:858-866.

113. Abi-Younes S, Sauty A, Mach F, et al. The stromal cell–derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. *Circ Res.* 2000;86:131-138.

114. Mach F, Sauty A, Jarossi AS, et al. Differential expression of three T lymphocyte–activating CXC chemokines by human atheroma-associated cells. *J Clin Invest.* 1999;104:1041-1050.

115. Haque NS, Zhang X, French DL, et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. *Circulation.* 2000;102:786-792.

116. Gasling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. *J Clin Invest.* 1999;103:773-778.

117. Egashira K, Koyanagi M, Kitamoto S, et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. *FASEB J.* 2000;14:1974-1978.

118. Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis. *J Clin Invest.* 2003;111:333-340.

119. Combadiere C, Potteaux S, Gao JL, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. *Circulation.* 2003;107:1009-1016.

120. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. *Circ Res.* 2001;89:401-407.

121. Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. *J Clin Invest.* 1991;88:1121-1127.

122. Wilcox JN, Nelken NA, Coughlin SR, et al. Local expression of inflammatory cytokines in human atherosclerotic plaques. *J Atheroscler Thromb.* 1994;1(suppl 1):S10-S13.

123. Romano M, Diomedè L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. *Lab Invest.* 2000;80:1095-1100.

124. Heney D, Whicher JT. Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. *Ann Clin Biochem.* 1995;32(pt 4):358-368.

125. Thomas CM, Sweep CG. Serum tumor markers: past, state of the art, and future. *Int J Biol Markers.* 2001;16:73-86.

126. Sturgeon CM. Tumor markers in the laboratory: closing the guideline-practice gap. *Clin Biochem.* 2001;34:353-359.

127. Corsi MM, Leone G, Fulgenzi A, et al. RANTES and MCP-1 chemokine plasma levels in chronic renal transplant dysfunction and chronic renal failure. *Clin Biochem.* 1999;32:455-460.

128. Aliberti J, Reis e Sousa C, Schito M, et al. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. *Nat Immunol.* 2000;1:83-87.

129. Wong CK, Lam CW. Clinical applications of cytokine assays. *Adv Clin Chem.* 2003;37:1-46.

130. Mire-Sluis AR. Cytokine and growth factor standardization: the need for research to answer modern issues. *Dev Biol Stand.* 1999;100:83-93.

131. Mahajan SD, Schwartz SA, Nair MP. Immunological assays for chemokine detection in in-vitro culture of CNS cells [serial online]. *Biol Proced Online.* 2003;5:90-102.

132. Szeplak Z, Koch AE. Immunoperoxidase histochemistry for chemokine detection in in-vitro culture of CNS cells. *Biol Proced Online.* 2003;5:90-102.

133. Morgan E, Varro R, Sepulveda H, et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. *Clin Immunol.* 2004;110:252-266.